RxDoctor Payments Data

Christopher Bullin

Optometrist · Jackson, MSNPI 1457541450

Payments from drug & device makers

$1,561in general payments, 2019–2025

Across 74 payments — averaging $21.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$397
  • Aerie Pharmaceuticals, Inc.$383
  • Alcon$309
  • Glaukos Corporation$135
  • Bausch & Lomb Americas Inc.$82
  • Tarsus Pharmaceuticals, Inc.$80
  • plus $176 from 5 others

What the payments were for

  • Food & beverage$1,561100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,561 in reported general payments places this provider in the 70th percentile of 372 optometrist providers in Mississippi.

See all optometrist providers in Mississippi

Medicare billing

Part B allowed, 2024
$26,951
Medicare patients
151
Services billed
342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine139$224,856
LumiganBimatoprost311$151,063
CombiganBrimonidine Tartrate/Timolol249$113,851
RocklatanNetarsudil Mesylat/Latanoprost195$102,544
VyzultaLatanoprostene Bunod62$29,318
RhopressaNetarsudil Mesylate44$29,312
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol118$16,801
ZerviateCetirizine Hcl21$12,820
AlrexLoteprednol Etabonate22$10,062
Lotemax SmLoteprednol Etabonate37$8,986
Cyclosporine11$6,816
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat357$6,108
Azelastine Hcl129$5,808
Latanoprost808$5,272
Loteprednol Etabonate20$3,593

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$397$489,771699 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$383$131,856239 claims
Bausch & Lomb Americas Inc.Vyzulta$82$29,31862 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Lotemax Sm, Loteprednol Etabonate$61$22,64179 claims
Eyevance Pharmaceuticals LLCZerviate$38$12,82021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 372 optometrist providers in Mississippi.

Other optometrist in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →